Stay updated on MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Sign up to get notified when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.

Latest updates to the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe page history shows Revision v3.3.4 added and Revision v3.3.3 removed.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page history shows an added Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure link, along with a prior Revision: v3.3.2; These are admin-level updates to the page metadata/footer and do not affect study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision: v3.3.2 added to the page history, replacing v3.2.0 and reflecting a platform/UI update rather than changes to study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page no longer displays a government funding and operating status notice that appeared at the top; this change does not affect the study record or its data.SummaryDifference0.5%

- Check75 days agoChange DetectedThe old and new screenshots show minor UI/layout adjustments on the Record History page, while the version list and navigation remain unchanged. There is no change to core study data, status, or substantive content.SummaryDifference0.1%

- Check103 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference10%

Stay in the know with updates to MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEK162 vs Dacarbazine in NRAS+ Melanoma Clinical Trial page.